| Autor: |
Amirani, Elaheh, Aghadavod, Esmat, Shafabakhsh, Rana, Asemi, Zatollah, Tabassi, Zohreh, Panahandeh, Ida, Naderi, Fatemeh, Abed, Alireza |
| Předmět: |
|
| Zdroj: |
Journal of Maternal-Fetal & Neonatal Medicine; Jun2022, Vol. 35 Issue 11, p2085-2090, 6p |
| Abstrakt: |
The aim of this study was to evaluate the effects of thiamin supplementation on biomarkers of inflammation and oxidative stress in patients with gestational diabetes mellitus (GDM). This randomized, double-blind, placebo-controlled trial was conducted among 60 patients with GDM. Patients were randomly allocated into two groups to receive either 100 mg/day thiamin supplements (n = 30) or placebo (n = 30) for 6 weeks. Thiamin supplementation significantly decreased serum high-sensitivity C-reactive protein (hs-CRP) (β − 0.98 mg/L; 95% CI, −1.54, −0.42; p =.001) and plasma malondialdehyde (MDA) levels (β − 0.86 µmol/L; 95% CI, −1.15, −0.57; p <.001) when compared with the placebo. In addition, thiamin supplementation downregulated gene expression of tumor necrosis factor-alpha (TNF-α) (p =.002) in peripheral blood mononuclear cells of patients with GDM. Thiamin supplementation did not affect other biomarkers of inflammation and oxidative stress. Overall, thiamin supplementation for 6 weeks to patients with GDM significantly reduced hs-CRP and MDA levels, and gene expression of TNF-α, but did not affect other biomarkers of inflammation and oxidative stress. Clinical Trials.govIdentifier no. http://www.irct.ir: IRCT20170513033941N58. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
